Sun, Apr 20, 2014, 4:53 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

La Jolla Pharmaceutical Co. Message Board

sprinterman1 221 posts  |  Last Activity: 7 hours ago Member since: Dec 2, 1999
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Estimated Completion Date

    by patlabors Apr 18, 2014 10:04 AM
    sprinterman1 sprinterman1 7 hours ago Flag

    ttt

  • CONAKRY , Guinea, April 18 (UPI) -- The deadly Ebola virus ravaging Guinea emerged locally, and is a different strain of virus from one discovered in central Africa, virologists confirmed.
    The spread of Ebola from Guinea, in western Africa, to neighboring Liberia, has panicked a region with poor health care and porous borders, and has killed 122 people, according to the World Health Organization. Scientists examined the virus genome and learned it is distinct from strains in countries such as Uganda, South Sudan, and democratic Republic of Congo, where Ebola was already known to circulate.

    Blood tests from victims determined the disease was not introduced from central Africa.

    A study published this week in the New England Journal of Medicine suggested “a single introduction of the virus into the human population” prior to December 2013, adding, “it is suspected that the virus was transmitted for months before the outbreak became apparent.”

    The virus is transmitted by human contact.

    The study said fruit bats, found throughout western Africa, were “potential reservoirs” of the virus.

  • It's beginning to feel like SARS revisited. For some of the scientists and doctors who helped the world battle the 2003 SARS outbreak, the recent rapid rise in human infections in several Middle Eastern countries caused by a cousin virus is creating a sense of sharp unease. Cases of Middle Eastern respiratory syndrome — MERS — have shot up markedly in the past month, driven it appears by outbreaks in hospitals or among health-care workers in Jeddah, Saudi Arabia, and in Abu Dhabi, in the United Arab Emirates."It does kind of bring flashbacks to SARS when we're seeing more health-care associated infections. Obviously that was a big challenge here in Toronto," says Dr. Kamran Khan, an infectious diseases physician at Toronto's St. Michael's Hospital who specializes in using airline traffic data to predict the international movement of diseases. In late March the global total of confirmed MERS cases crossed the 200 mark, two years after the first known infections occurred. By late Saturday, the combined global count announced by the World Health Organization and national governments was closing in on 290 cases.If all are confirmed, it will mean 28 per cent of all MERS cases will have been reported in the last month.This week has also brought word that an event many dread but see as inevitable has again happened. MERS has spread from the Middle East to other countries.

  • It's beginning to feel like SARS revisited. For some of the scientists and doctors who helped the world battle the 2003 SARS outbreak, the recent rapid rise in human infections in several Middle Eastern countries caused by a cousin virus is creating a sense of sharp unease. Cases of Middle Eastern respiratory syndrome — MERS — have shot up markedly in the past month, driven it appears by outbreaks in hospitals or among health-care workers in Jeddah, Saudi Arabia, and in Abu Dhabi, in the United Arab Emirates."It does kind of bring flashbacks to SARS when we're seeing more health-care associated infections. Obviously that was a big challenge here in Toronto," says Dr. Kamran Khan, an infectious diseases physician at Toronto's St. Michael's Hospital who specializes in using airline traffic data to predict the international movement of diseases. In late March the global total of confirmed MERS cases crossed the 200 mark, two years after the first known infections occurred. By late Saturday, the combined global count announced by the World Health Organization and national governments was closing in on 290 cases.If all are confirmed, it will mean 28 per cent of all MERS cases will have been reported in the last month.This week has also brought word that an event many dread but see as inevitable has again happened. MERS has spread from the Middle East to other countries.

  • Reply to

    Biotech

    by sprinterman1 Apr 18, 2014 11:35 AM
    sprinterman1 sprinterman1 Apr 18, 2014 1:31 PM Flag

    I don't mind at all.

  • sprinterman1 by sprinterman1 Apr 18, 2014 11:35 AM Flag

    8/18/2008 JAZZ was at $8.07 down from $13.18 on 8/13/2007. By March 9, 2009 JAZZ was a .74 cents. By 9/9/2009 JAZZ was at $9.19. By 9/5/2011 it was at $41.81. Yesterday it closed at $136.15. There was a lot of fluctuations between. Anyone who bought this stock at any of the points cited and held it has some spare change in his/her pocket today. Will be interesting where Inovio will be in 2019?

  • MANILA, Philippines—The Department of Foreign Affairs (DFA) warned Tuesday all Overseas Filipino Workers (OFWs) in the Middle East on the breakout of the deadly disease in the region that has claimed the life of a Filipino and affected five others

  • Dr. J. Joseph Kim, Inovio's President and CEO, said, "Our SynCon® platform has again generated a synthetic vaccine candidate that shows promise for providing a treatment where there is none. With human data showing the powerful killing effect of T cells generated by our vaccine for HIV and our therapy for HPV-associated cervical dysplasia and various cancers, we look forward to providing Inovio's answer to MERS, a deadly infectious disease that has unknown pandemic potential. What's even more impressive about our candidate vaccine is that it is designed with the goal to universally protect against multiple strains of MERS, which has been shown to have diverse genetic variants. With appropriate external funding, this product could become an effective shield against this deadly virus."

    To begin the study, a consensus MERS "spike" protein vaccine construct was created based on multiple strains of the MERS virus. Inovio's MERS DNA vaccine was immunogenic in mice and seroconversion, or the development of detectable specific antibodies in the blood as a result of immunization, was observed in all animals. Furthermore, the antibodies generated by the vaccine in 100% of mice (20 of 20) were able to neutralize or completely block actual infection of MERS virus in the cells, demonstrating the protective potential of this vaccine. In contrast, none of the unvaccinated mice in the control group (10) generated neutralizing antibodies.

    Researchers also observed that vaccination was highly T-cell immunogenic, generating robust and broad T cell responses as extensively analyzed by the standardized T cell ELISPOT assay. The vaccine produced robust CD8+ and CD4+ T cell responses against multiple epitopes of the MERS spike protein. This increased diversity and magnitude of cellular responses may be critical for effectively mitigating MERS infection

  • sprinterman1 sprinterman1 Apr 17, 2014 3:26 PM Flag

    6) Can a request for breakthrough therapy designation be submitted for multiple indications of the same drug?
    Yes. A breakthrough therapy designation may apply to a combination of a drug (either alone or in combination with other drugs) and the specific use for which it is being studied. Therefore, a separate breakthrough designation request must be submitted for each proposed development program (i.e., each indication for a drug (or drug combination)).

  • sprinterman1 sprinterman1 Apr 17, 2014 2:58 PM Flag

    Well then, why don't you give IR a call and set them straight as the statement is straight from the Investor presentation PDF on the website. You seem to be knowledgeable and an investor. I'm sure management would appreciate the input as do I.

  • (Keywords, "path forward", "expansion", "broader platform validation")
    •Efficacy data
    •Path forward to phase III for CIN 2/3
    •Expansion of product use to other HPV-related indications (cervical cancer, head/neck cancers, and anogenital cancers)
    •Seek orphan designation potential
    •T cell and safety data
    •Broader platform validation for all Inovio immunotherapy products in the pipeline

  • The operative word here is "all".

  • I love that word "immunogenicity".

  • sprinterman1 sprinterman1 Apr 17, 2014 9:36 AM Flag

    Yep, I found the old one poking around Inovio's website. Here are the bullet points from page 7 of the old investor presentation. It cited greater than 400 whereas the new presentation is indicating 500. I would guess there are more changes that need to be discovered. All you smart guys/gals dig in and see what's new.

    •T cells are vital to clearing cancerous or infected cells
    •Active immuno-therapies: harnessing the power of T cells
    •Inovio’s DNA immunotherapies displaying best-in-class T cells
    •Functional killing effect
    •Safe and well tolerated
    • 400 patents globally

  • Reply to

    This was posted on the VGXI website

    by sprinterman1 Apr 16, 2014 11:23 AM
    sprinterman1 sprinterman1 Apr 16, 2014 11:30 AM Flag

    Nothing like having a conversation with yourself :)

  • Reply to

    This was posted on the VGXI website

    by sprinterman1 Apr 16, 2014 11:23 AM
    sprinterman1 sprinterman1 Apr 16, 2014 11:29 AM Flag

    Talk about having your ducks in a row. This Dr. Kim is 10 steps ahead on everything.

  • Reply to

    This was posted on the VGXI website

    by sprinterman1 Apr 16, 2014 11:23 AM
    sprinterman1 sprinterman1 Apr 16, 2014 11:27 AM Flag

    VGXI would also like to congratulate Inovio Pharmaceuticals for winning the 2014 ViE Award in the category of Best Therapeutic Vaccine for their VGX-3100 DNA Vaccine, manufactured by VGXI.

  • Reply to

    This was posted on the VGXI website

    by sprinterman1 Apr 16, 2014 11:23 AM
    sprinterman1 sprinterman1 Apr 16, 2014 11:26 AM Flag

    VGXI Wins 2014 Vaccine Industry Excellence (ViE) Award for Best Contract Manufacturing Organization

    VGXI announced today that the corporation won the award for Best CMO at the 7th Annual ViE Awards Ceremony held at the 2014 World Vaccine Congress in Washington, D.C.

  • "Roche and Inovio Pharmaceuticals partner on Inovio’s prostate cancer and hepatitis B immunotherapy products"

    So, would all production be run though VGXI. This is a wholly owned subsidiary correct. Are that set up to handle all anticipated production for INO, and possibly Roche?

LJPC
10.02+0.88(+9.63%)Apr 17 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Sonoco Products Co.
NYSEThu, Apr 17, 2014 4:00 PM EDT